Kallisio wins CE mark for Stentra in head and neck radiotherapy

Kallisio said its Stentra intraoral positioning system has received CE certification under the European Union Medical Device Regulation, clearing the way for commercialization across the European Economic Area, with initial pilot deployment planned in Germany. Stentra is a patient-specific, 3D-printed oral immobilization device used during head and neck radiation therapy planning and treatment to position the jaw and tongue and help move healthy tissue away from the radiation field. The company already has U.S. FDA 510(k) clearance for the device, granted under K232293, and says the system is designed to fit into existing radiation oncology workflows without changes to treatment planning software or IT systems. (streetinsider.com)

Why it matters: For veterinary professionals, this is a human medtech development worth watching because it reflects the broader shift toward patient-specific, 3D-printed immobilization tools in radiation oncology. Reviews of intraoral stents in head and neck radiotherapy suggest these devices may help reduce dose to healthy oral structures and lower treatment-related complications such as mucositis, xerostomia, and trismus, though the evidence base is still developing. That kind of workflow-friendly personalization could eventually have relevance for specialty veterinary oncology centers using advanced radiation protocols, especially where reproducible positioning and normal-tissue sparing are priorities. (pubmed.ncbi.nlm.nih.gov)

What to watch: Watch for early German pilot-site uptake, any published clinical outcomes from ongoing stent studies, and whether Kallisio expands beyond Europe with additional reimbursement or market-access milestones. (streetinsider.com)